RecruitingPhase 1NCT04732065
ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
Studying Diffuse intrinsic pontine glioma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sabine Mueller, MD, PhD
- Principal Investigator
- Sabine Mueller, MD, PhDUniversity of California, San Francisco
- Intervention
- ONC206(drug)
- Enrollment
- 208 enrolled
- Eligibility
- 2-21 years · All sexes
- Timeline
- 2021 – 2027
Study locations (6)
- University of California, San Francisco, San Francisco, California, United States
- Emory University, Atlanta, Georgia, United States
- University of Michigan, Ann Arbor, Michigan, United States
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands
- The University Children's Hospital in Zurich, Zurich, Canton of Zurich, Switzerland
Collaborators
Jazz Pharmaceuticals · Mithil Prasad Foundation · Storm the Heavens Fund · The ChadTough Defeat DIPG Foundation · National Cancer Institute (NCI) · Dana-Farber Cancer Institute
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04732065 on ClinicalTrials.govOther trials for Diffuse intrinsic pontine glioma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07076498Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standard of Care RadiationM.D. Anderson Cancer Center
- RECRUITINGPHASE1, PHASE2NCT07501156H3K27M-specific Immune Effector Cells Targeting DMG/DIPGShenzhen Geno-Immune Medical Institute
- RECRUITINGPHASE2NCT06838676ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade GliomasNationwide Children's Hospital
- RECRUITINGPHASE1NCT06305910CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young AdultsOX2 Therapeutics
- RECRUITINGPHASE1NCT06221553Safety and Efficacy of Loco-regional B7H3 IL-7Ra CAR T Cell in DIPGChulalongkorn University
- RECRUITINGPHASE1NCT05544526CAR T Cells to Target GD2 for DMGUniversity College, London
- RECRUITINGPHASE1NCT05762419FUS Etoposide for DMGColumbia University
- ACTIVE NOT RECRUITINGPHASE1NCT05768880Study of B7-H3, EGFR806, HER2, And IL13-Zetakine (Quad) CAR T Cell Locoregional Immunotherapy For Pediatric Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, And Recurrent Or Refractory Central Nervous System TumorsSeattle Children's Hospital